12:00 AM
 | 
Aug 10, 2009
 |  BC Week In Review  |  Company News  |  Deals

Altair Nanotechnologies, Spectrum Pharmaceuticals deal

The partners added non-human indications to a 2005 deal that granted Spectrum exclusive, worldwide rights to develop and commercialize Altair's RenaZorb family of compounds...

Read the full 107 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >